Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-877-4
CAS number: 89-04-3
The substance is expected to be poorly absorbed through the gastro-intestinal tract following oral administration. If absorbed it is eliminated relatively rapidly, mainly via the urine as polar metabolites. In-silico evaluation suggests dermal absorption is not significant.
The phthalate esters have been extensively studied and various reviews
of different phthalate esters by the Australian National Industrial
Chemicals Notification and Assessment Scheme (NICNAS) are available. The
data on the toxicokinetics indicate that phthalates in general are
likely to be absorbed as the mono-ester from the gastro-intestinal tract
following hydrolysis of the di-ester and excreted via the urine.
The similarity in toxicokinetic behaviour with the phthalate esters is
supported by data on the absorption, distribution, metabolism and
elimination of a structural analogue of the substance (tris-(2
-ethylhexyl)trimellitate), in which the ester chains are C-8 branched
rather than C-8 linear. Rats were administered a single oral dose of the
radiolabelled substance. Recovery of the administered dose was 94% with
approximately 75% eliminated unchanged in the faeces, 16.3% found in the
urine and 1.9% in expired air. Residual radioactivity in the carcass
after 6 days was <0.6% of the administered dose. Findings indicate that
the substance may be partially hydrolysed in the gastro-intestinal tract
to the alcohol and corresponding di-ester and, following further
hydrolysis, the mono-ester. Only 2 -ethylhexanol and a single isomer of
mono-(2 -ethylhexyl)trimellitate appear to be absorbed. Following
absorption, 2-ethylhexanol was extensively metabolised with metabolites
eliminated in the urine and as expired14CO2.There was no evident
metabolism of mono-(2-ethylhexyl)trimellitate, this being eliminated
unchanged. Urinary excretion of radioactivity was bi-phasic with
half-lives of 3.1 and 42 hours.
In summary, available toxicokinetic studies show that the substance is
expected to be poorly absorbed through the gastro-intestinal tract
following oral administration. If absorbed it is eliminated relatively
rapidly, mainly via the urine as polar metabolites.
In-silico evaluation of dermal absorption indicates that after 4 hours
there is no amount of deposited trioctyl benzene-1,2,4-tricarboxylate
that is absorbed within viable epidermis and therefore that could enter
in systemic circulation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again